<Suppliers Price>

Intetumumab

Names

[ CAS No. ]:
725735-28-4

[ Name ]:
Intetumumab

Biological Activity

[Description]:

Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> JAK/STAT Signaling >> EGFR
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[In Vitro]

Intetumumab (CNTO 95; 0-5 μg/mL; 20 分钟; USPC-ARK-3 细胞) 抑制整合素介导的 USPC 细胞粘附于玻璃连素底物，并抑制血清诱导的 USPC 细胞迁移[1]。

[In Vivo]

Intetumumab (CNTO 95; 10 mg/kg; i.p.; 雄性裸大鼠) 抑制肿瘤生长，抑制 A549 肿瘤的自发肺转移，减少发生肺转移的大鼠数量和每个肺的转移病灶数量[2]。 Animal Model: Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)[2] Dosage: 10 mg/kg Administration: Intraperitoneal injection; once a week for 60 days Result: Had the total tumor response rates (CR and PR) was 33% in A549 tumor model. Developed lung metastases only 4 of 9 rats.

[References]

[1]. Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90.  

[2]. Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.  

Chemical & Physical Properties

[ Molecular Weight ]:
145.6 (kDa)

Related Compounds